Apollo Management Holdings’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$216K Hold
307,987
﹤0.01% 76
2025
Q4
$477K Hold
307,987
﹤0.01% 97
2025
Q3
$487K Hold
307,987
0.01% 42
2025
Q2
$671K Hold
307,987
0.01% 38
2025
Q1
$841K Hold
307,987
0.02% 36
2024
Q4
$1.28M Hold
307,987
0.02% 38
2024
Q3
$1.2M Hold
307,987
0.02% 33
2024
Q2
$1.21M Hold
307,987
0.02% 36
2024
Q1
$1.29M Hold
307,987
0.02% 39
2023
Q4
$1.45M Hold
307,987
0.01% 42
2023
Q3
$961K Hold
307,987
0.01% 52
2023
Q2
$1.41M Hold
307,987
0.01% 57
2023
Q1
$1.52M Buy
307,987
+64,603
+27% +$318K 0.01% 105
2022
Q4
$1.33M Hold
243,384
0.01% 131
2022
Q3
$1.58M Hold
243,384
0.01% 154
2022
Q2
$1.15M Hold
243,384
0.01% 178
2022
Q1
$1.7M Hold
243,384
0.01% 241
2021
Q4
$2.48M Hold
243,384
0.01% 165
2021
Q3
$2.97M Buy
+243,384
New +$3.67M 0.01% 102

Other funds holding MXCT

Apollo Management Holdings's MXCT Position: Q1 2026 in Review

Apollo Management Holdings held its MaxCyte (MXCT) position steady in Q1 2026 at 307,987 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #76.

Apollo Management Holdings first reported a position in MXCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.97M in Q3 2021. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Apollo Management Holdings held 307,987 shares of MaxCyte worth $216K as of Q1 2026.
  • Apollo Management Holdings left its MaxCyte share count unchanged in Q1 2026.
  • MaxCyte made up ﹤0.01% of Apollo Management Holdings's portfolio in Q1 2026, its #76 holding.
  • Apollo Management Holdings first reported a position in MaxCyte in Q3 2021 and has held it in 19 quarters since.
  • Apollo Management Holdings's MaxCyte position peaked at $2.97M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Apollo Management Holdings's 13F filing for Q1 2026, filed 15 May 2026.